Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 13 (Search time: 0.003 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2002
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant
Frost, M.
;
Ferrao, P.
;
Hughes, T.
;
Ashman, L.
2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination
Parker, W.
;
Phillis, S.
;
Yeung, D.
;
Hughes, T.
;
Scott, H.
;
Branford, S.
2016
Chronic myeloid leukemia: reminiscences and dreams
Mughal, T.
;
Radich, J.
;
Deininger, M.
;
Apperley, J.
;
Hughes, T.
;
Harrison, C.
;
Gambacorti-Passerini, C.
;
Saglio, G.
;
Cortes, J.
;
Daley, G.
2022
RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.
Shanmuganathan, N.
;
Wadham, C.
;
Thomson, D.
;
Shahrin, N.H.
;
Vignaud, C.
;
Obourn, V.
;
Chaturvedi, S.
;
Yang, F.
;
Feng, J.
;
Saunders, V.
;
Kok, C.H.
;
Yeung, D.
;
King, R.M.
;
Kenyon, R.R.
;
Lin, M.
;
Wang, P.
;
Scott, H.
;
Hughes, T.
;
Schreiber, A.W.
;
Branford, S.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2013
NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis
Watkins, D.
;
Hughes, T.
;
White, D.
;
D'Andrea, R.
2010
Practical considerations for monitoring patients with chronic myeloid leukemia
Branford, S.
;
Hughes, T.
2004
Clinical resistance to imatinib: mechanisms and implications
Hochhaus, A.
;
Hughes, T.
2009
Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Branford, S.
;
Soverini, S.
;
Kim, J.
;
Muller, M.
;
Martinelli, G.
;
Cortes, J.
;
Beppu, L.
;
Gottardi, E.
;
Dongho, K.
;
Erben, P.
;
Shou, Y.
;
Haque, A.
;
Gallagher, N.
;
Radich, J.
;
Hochhaus, A.
Discover
Author
7
Branford, S.
5
Hochhaus, A.
4
Cortes, J.
4
Radich, J.
4
Saglio, G.
3
Kim, D.
2
Apperley, J.
2
Erben, P.
2
Larson, R.
2
Martinelli, G.
.
next >
Subject
12
Humans
11
Leukemia, Myelogenous, Chronic, B...
10
Fusion Proteins, bcr-abl
9
Pyrimidines
8
Benzamides
8
Imatinib Mesylate
8
Piperazines
6
Antineoplastic Agents
4
Drug Resistance, Neoplasm
4
Prognosis
.
next >
Date issued
1
2020 - 2022
5
2010 - 2019
7
2002 - 2009